Here is Eli Lilly’s competitive edge in GLP-1 obesity drugs and Abbott’s secondary play

Health, Fitness & Food

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.)

Products You May Like

Articles You May Like

Embattled Abbott Labs comes through with a strong quarter, buyback announcement
Why Do Some WNBA Players Wear One Leg Sleeve?
Slow Cooker Shredded Chicken
Can Your Period Increase the Risk of a Sports Injury? Here’s What a Doctor Says
Nvidia, Google, Microsoft and more head to Las Vegas to tout health-care AI tools

Leave a Reply

Your email address will not be published. Required fields are marked *